| Zeven (dalbavancin) / RaQualia, AbbVie |
NCT02127970 / 2014-000419-15: Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections |
|
|
| Completed | 3b | 698 | US, Europe, RoW | Dalbavancin, DALVANCE®, Dalbavancin-matching Placebo | Durata Therapeutics Inc., an affiliate of Allergan plc | Abscess, Wound Infection, Surgical Site Infection, Cellulitis | 03/15 | 03/15 | | |
| Completed | 3 | 573 | US, Canada, Europe, RoW | Dalbavancin, Vancomycin / Linezolid | Durata Therapeutics Inc., an affiliate of Allergan plc | Abscess, Wound Infection, Surgical Site Infection, Cellulitis | 09/12 | 11/12 | | |
| Completed | 3 | 739 | US, Europe, RoW | IV Dalbavancin, Vancomycin/Linezolid | Durata Therapeutics Inc., an affiliate of Allergan plc | Abscess, Wound Infection, Surgical Site Infection, Cellulitis | 11/12 | 12/12 | | |
| Withdrawn | 3 | 0 | US | Dalbavancin, Dalvance, Linezolid, Zyvox, Linezolid Placebo, Azithromycin | Durata Therapeutics Inc., an affiliate of Allergan plc | Community Acquired Pneumonia | 11/16 | 12/16 | | |
| Withdrawn | 3 | 0 | US | Dalbavancin, Dalvance, cefazolin, nafcillin, oxacillin or vancomycin | Durata Therapeutics International BV (an Affiliate of Actavis, Inc.) | Osteomyelitis | 10/18 | 04/19 | | |
| Not yet recruiting | 3 | 406 | Europe | Dalbavancin, Powder for concentrate for solution for injection/infusion, Xydalba | CENTRE HOSPITALIER ANNECY GENEVOIS, French Ministery of Health (DGOS), ADVANZ Pharma | Staphylococcus aureus catheter bloodstream infection, Bloodstream infection caused by the bacterium Staphylococcus aureus in patients with a catheter and with a low risk for S. aureus associated complications, Diseases [C] - Bacterial Infections and Mycoses [C01] | | | | |
NCT02814916 / 2014-005281-30: Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA |
|
|
| Completed | 3 | 199 | Europe, US, RoW | Dalbavancin, Xydalba, Vancomycin, Oxacillin, Flucloxacillin, Cefadroxil, Clindamycin | AbbVie | Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections, Staphylococcal Skin Infections | 01/24 | 01/24 | | |
DALICATH, NCT05117398: Dalbavancin Versus Standard Antibiotic Therapy for Catheter-related Bloodstream Infections Due to Staphylococcus Aureus |
|
|
| Recruiting | 3 | 406 | Europe | Dalbavancin administration, Xydalba® administration, Standard antibiotic therapy, Standard documented antibiotic therapy | Assistance Publique - Hôpitaux de Paris, Centre Hospitalier de Perigueux, Advanz Pharma, Nantes University Hospital, Centre National de Référence des staphylocoques | Catheter Bacteremia, Staphylococcus Aureus Infection | 09/25 | 09/26 | | |
SUDDEN-OUT, NCT04847921: Substance Use Disorder (SUD)-Associated Infections' Treatment With Dalbavancin ENabling OUtpatient Transition |
|
|
| Terminated | 2/3 | 11 | US | Dalbavancin, Dalvance | University of Colorado, Denver | Gram-Positive Bacterial Infections, Gram-Positive Bacteraemia, Substance Use Disorders, Intravenous Substance Abuse | 10/23 | 10/23 | | |
